Noninvasive staging of non-small cell lung cancer: ACCP evidenced-based clinical practice guidelines (2nd edition)

Chest

Volumn 132, Issue 3 SUPPL., 2007, Pages 178S-201S

  Silvestri, Gerard A ^a   Gould, Michael K ^b   Margolis, Mitchell L ^c   Tanoue, Lynn T ^d   McCrory, Douglas ^f   Toloza, Eric ^f   Detterbeck, Frank ^e  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d YALE UNIVERSITY   (United States)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

CT scan; Lung cancer; Mediastinum; Metastases; Noninvasive; Positron emission tomography; Staging

Indexed keywords

CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; HUMAN; LUNG BIOPSY; LUNG NON SMALL CELL CANCER; MEDIASTINUM METASTASIS; NON INVASIVE MEASUREMENT; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SENSITIVITY AND SPECIFICITY; ARTICLE; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; EVIDENCE BASED MEDICINE; LUNG TUMOR; LYMPH NODE METASTASIS; PATHOLOGY;

CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIALS; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED;

EID: 34848895759     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.07-1360     Document Type: Article

References (183)

1. Darling GE. Staging of the patient with small cell lung cancer. Chest Surg Clin N Am 1997; 7:81-94
2. Mountain CF. A new international system for staging lung cancer. Chest 1986; 89(suppl):225s-233s
3. Mountain C. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
4. Toloza E, Harpole L, McCrory DC. Noninvasive staging of non-small cell lung cancer: a review of the current evidence. Chest 2003(suppl):137s-146s
5. Cerfolio RJ, Bryant AS, et al. Improving the inaccuracies of clinical staging of patients with NSCLC: a prospective trial. Ann Thorac Surg 2005; 80:1207-1214
6. Pozo-Rodriquez F, Martin de Nicolas JL, Sanchez-Nistal MA, et al. Accuracy of helical computed tomography and (18 F) flourodeoxyglucose positron emission tomography for identifying lymph node mediastinal metastases in potentially resectable non-small-cell lung cancer. J Clin Oncol 2005; 23:8348-8356
7. Serra M, Cirera L, et al. Routine positron tomography (PET) and selective mediastinoscopy is as good as routine mediastinoscopy to rule out N2 disease in non-small cell lung cancer (NSCLC) [abstract]. J Clin Oncol 2006; 24:371s
8. Verhagen AFT, Bootsma GP, Tjan-Heijnen VCG, et al. FDG-PET in staging lung cancer: how does it change the algorithm? Lung Cancer 2004; 44:175-181
9. Bollen E, Goei R, Hof-Grootenboer B, et al. Interobserver variability and accuracy of computed tomographic assessment of nodal status in lung cancer. Ann Thorac Surg 1994; 58:158-162
10. Ratto GB, Frola C, Cantoni S, et al. Improving clinical efficacy of computed tomographic scan in the preoperative assessment of patients with non-small cell lung cancer. J Thorac Cardiovasc Surg 1990; 99:416-425
11. Nomori H, Watanabe K, Ohtsuka T, et al. The size of metastatic foci and lymph nodes yielding false-negative and false-positive lymph node staging with positron emission tomography in patients with lung cancer. J Thorac Cardiovasc Surg 2004; 127:1087-1092
12. Takamochi K, Yoshida J, Murakami K, et al. Pitfalls in lymph node staging with positron emission tomography in non-small cell lung cancer patients. Lung Cancer 2005; 47:235-242
13. Webb W, Gatsonis C, Zerhouni E, et al. CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group. Radiology 1991; 178:705-713
14. Cole PH, Roszkowski A, Firouz-Abadi A, et al. Computerised tomography does not predict N2 disease in patients with lung cancer. Aust N Z J Med 1993; 23:688-691
15. Jolly PC, Hutchinson CH, Detterbeck F, et al. Routine computed tomographic scans, selective mediastinoscopy, and other factors in evaluation of lung cancer. J Thorac Cardiovasc Surg 1991; 102:266-270
16. McLoud T, Bourgouin P, Greenberg R, et al. Bronchogenic carcinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling. Radiology 1992; 182:319-323
17. Yokoi K, Okuyama A, Mori K, et al. Mediastinal lymph node metastasis from lung cancer: evaluation with T1-201 SPECT-comparison with CT. Radiology 1994; 192:813-817
18. Primack SL, Lee KS, Logan PM, et al. Bronchogenic carcinoma: utility of CT in the evaluation of patients with suspected lesions. Radiology 1994; 193:795-800
19. Aaby C, Kristensen S, Nielsen SM. Mediastinal staging of non-small-cell lung cancer: computed tomography and cervical mediastinoscopy. ORL J Otorhinolaryngol Relat Spec 1995; 57:279-285
20. Bury T, Dowlati A, Paulus P, et al. Whole-body 18FDG positron emission tomography in the staging of non-small cell lung cancer. Eur Respir J 1997; 10:2529-2534
21. Buccheri G, Biggi A, Ferrigno D, et al. Anti-CEA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer. Thorax 1996; 51:359-363
22. Bury T, Paulus P, Dowlati A, et al. Staging of the mediastinum: value of positron emission tomography imaging in non-small cell lung cancer. Eur Respir J 1996; 9:2560-2564
23. Gdeedo A, Van Schil P, Corthouts B, et al. Prospective evaluation of computed tomography and mediastinoscopy in mediastinal lymph node staging. Eur Respir J 1997; 10:1547-1551
24. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. FDG-PET scan in potentially operable non-small cell lung cancer: do anatometabolic PET-CT fusion images improve the localization of regional lymph node metastases? Eur J Nucl Med 1998; 25:1495-1501
25. Vansteenkiste JF, Stroobants SG, De Leyn PR, et al. Lymph node staging in non-small-cell lung cancer with FDG-PET scan: a prospective study on 690 lymph node stations from 68 patients. J Clin Oncol 1998; 16:2142-2149
26. Suzuki K, Nagai K, Yoshida J, et al. Clinical predictors of N2 disease in the setting of a negative computed tomographic scan in patients with lung cancer. J Thorac Cardiovasc Surg 1999; 117:593-598
27. Saunders CAB, Dussek JE, O'Doherty MJ, et al. Evaluation of fluorine-18-fluorodeoxyglucose whole body positron emission tomography imaging in the staging of lung cancer. Ann Thorac Surg 1999; 67:790-797
28. Marom E, McAdams H, Erasmus J, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212:803-809
29. Takamochi K, Naga IK, Yoshida J, et al. The role of computed tomographic scanning in diagnosing mediastinal node involvement in non-small cell lung cancer. J Thorac Cardiovasc Surg 2000; 119:1135-1140
30. Pieterman RM, van Putten JWG, Meuzelaar JJ, et al. Preoperative staging of non-small-cell lung cancer with positron-emission tomography. N Engl J Med 2000; 343:254-261
31. Osada H, Kojima K, Tsukada H, et al. Cost-effectiveness associated with the diagnosis and staging of non-small-cell lung cancer. Jpn J Thorac Cardiovasc Surg 2001; 49:1-10
32. Kamiyoshihara M, Kawashima O, Ishikawa S, et al. Mediastinal lymph node evaluation by computed tomographic scan in lung cancer. J Cardiovasc Surg 2001; 42:119-124
33. Dunagan DP, Chin R, McCain TW, et al. Staging by positron emission tomography predicts survival in patients with non-small cell lung cancer. Chest 2001; 119:333-339
34. Wallace MB, Silvestri GA, Sahai AV, et al. Endoscopic ultrasound-guided fine needle aspiration for staging patients with carcinoma of the lung. Ann Thorac Surg 2001; 1861-1867
35. Poncelet AJ, Lonneux M, Coche E, et al. PET-FDG scan enhances but does not replace preoperative surgical staging in non-small cell lung carcinoma. Eur J Cardiothorac Surg 2001; 20:468-474
36. Laudanski J, Kozlowski M, Niklinski J, et al. The preoperative study of mediastinal lymph nodes metastasis in lung cancer by endoscopic ultrasonography (EUS) and helical computed tomography (CT). Lung Cancer 2001; 34:s123-126
37. von Haag DW, Follette DM, Roberts PF, et al. Advantages of positron emission tomography over computed tomography in mediastinal staging of non-small cell lung cancer. J Surg Res 2002; 103:160-164
38. Nosotti M, Santambrogio L, Gasparini M, et al. Role of (99m)tc-hexakis-2-methoxy-isobutylisonitrile in the diagnosis and staging of lung cancer. Chest 2002; 122:1361-1364
39. Kiernan PD, Sheridan MJ, Lamberti J, et al. Mediastinal staging of non-small cell lung carcinoma using computed and positron-emission tomography. South Med J 2002; 95:1168-1172
40. Eggeling S, Martin T, Bottger J, et al. Invasive staging of non-small cell lung cancer-a prospective study. Eur J Cardiothorac Surg 2002; 22:679-684
41. Schillaci OSA, Scopinaro F, Monteleone F, et al. Mediastinal lymph node involvement in non-small cell lung cancer: evaluation with 99mTc-tetrofosmin SPECT and comparison with CT. J Nucl Med 2003; 44:1219-1224
42. Reed CE, Harpole DH, Posther KE, et al. Results of the American College of Surgeons Oncology Group Z0050 trial: the utility of positron emission tomography in staging potentially operable non-small cell lung cancer. J Thorac Cardiovasc Surg 2003; 126:1943-1951
43. Kimura H, Iwai N, Ando S, et al. A prospective study of indications for mediastinoscopy in lung cancer with CT findings, tumor size, and tumor markers. Ann Thorac Surg 2003; 75:1734-1739
44. Kelly RF, Tran T, Holmstrom A, et al. Accuracy and cost-effectiveness of [18F]-2-fluoro-deoxy-D-glucose-positron emission tomography scan in potentially resectable non-small cell lung cancer. Chest 2004; 125:1413-1423
45. Gould MK, Kuschner WG, Rydzak CE, et al. Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med 2003; 139:879-892
46. Dwamena B, Sonnad S, Angobaldo J, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s; meta-analytic comparison of PET and CT. Radiology 1999; 213:530-536
47. American Thoracic Society, European Respiratory Society. Pretreatment evaluation of non-small cell lung cancer. Am J Respir Crit Care Med 1997; 156:320-332
48. British Thoracic Society, Society of Cardiothoracic Surgeons of GB, Ireland Working Party. Guidelines on the selection of patients with lung cancer for surgery. Thorax 2001; 56:89-106
49. Nolop K, Rhodes C, Brudin L, et al. Glucose utilization in vivo by human pulmonary neoplasms. Cancer 1987; 60:2682-2689
50. Weber G, Cantero A. Glucose-6-phosphatase activity in normal, pre-cancerous, and neoplastic tissues. Cancer Res 1955; 15:105-108
51. Wahl R, Hitchins GD, Buchsbaum D, et al. 18F-2 deoxy-2-fluoro-D-glucose uptake into human tumor xenografts: feasibility studies for cancer imaging with positron-emission tomography. Cancer 1991; 67:1544-1550
52. Gupta NC, Graeber GM, Bishop HA. Comparative efficacy of positron emission tomography with fluorodeoxyglucose in evaluation of small (1 cm), intermediate (1 to 3 cm), and large (>3 cm) lymph node lesions. Chest 2000; 117:773-778
53. Detterbeck FC, Falen S, Rivera MP, et al. Seeking a home for a PET: part 2. Defining the appropriate place for positron emission tomography imaging in the staging of patients with suspected lung cancer. Chest 2004; 125:2300-2308
54. Detterbeck FC, Falen S, Rivera MP, et al. Seeking a home for a PET: part 1. Defining the appropriate place for positron emission tomography imaging in the diagnosis of pulmonary nodules or masses. Chest 2004; 125:2294-2299
55. Kim BT, Kim Y, Lee KS, et al. Localized form of bronchioloalveolar carcinoma: FDG PET findings. AJR Am J Roentgenol 1998; 170:935-939
56. Higashi K, Ueda Y, Seki H, et al. Fluorine-18-FDG PET imaging is negative in bronchioloalveolar lung carcinoma. J Nucl Med 1998; 39:1016-1020
57. Gupta NC, Maloof J, Gunel E. Probability of malignancy in solitary pulmonary nodules using fluorine-18-FDG and PET. J Nucl Med 1996; 37:943-948
58. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med 2003; 348:2500-2507
59. Wahl RL, Quint LE, Greenough RL, et al. Staging of mediastinal non-small cell lung cancer with FDG PET, CT, and fusion images: preliminary prospective evaluation. Radiology 1994; 191:371-377
60. Chin RJ, Ward R, Keyes JW, et al. Mediastinal staging of non-small-cell lung cancer with positron emission tomography. Am J Respir Crit Care Med 1995; 152:2090-2096
61. Scott WJ, Gobar LS, Terry JD, et al. Mediastinal lymph node staging of non-small-cell lung cancer: a prospective comparison of computed tomography and positron emission tomography. J Thorac Cardiovasc Surg 1996; 111:642-648
62. Sazon DA, Santiago SM, Soo Hoo GW, et al. Fluorodeoxyglucose-positron emission tomography in the detection and staging of lung cancer. Am J Respir Crit Care Med 1996; 153:417-421
63. Steinert HC, Hauser M, Allemann F, et al. Non-small cell lung cancer: nodal staging with FDG PET versus CT with correlative lymph node mapping and sampling. Radiology 1997; 202:441-446
64. Guhlmann A, Storck M, Kotzerke J, et al. Lymph node staging in non-small cell lung cancer: evaluation by [18F] FDG positron emission tomography (PET). Thorax 1997; 52:438-441
65. Magnani P, Carretta A, Rizzo G, et al. FDG/PET and spiral CT image fusion for mediastinal lymph node assessment of non-small cell lung cancer patients. J Cardiovasc Surg 1999; 40:741-748
66. Roberts PF, Follette DM, von Haag D, et al. Factors associated with false-positive staging of lung cancer by positron emission tomography. Ann Thorac Surg 2000; 70:1154-1160
67. Liewald F, Grosse S, Storck M, et al. How useful is positron emission tomography for lymph node staging in non-small-cell lung cancer? Thorac Cardiovasc Surg 2000; 48:93-96
68. Farrell MA, McAdams HP, Herndon JE, et al. Non-small cell lung cancer: fDG PET for nodal staging in patients with stage I disease. Radiology 2000; 215:886-890
69. Tatsumi M, Yutani K, Nishimura T. Evaluation of lung cancer by 99mTc-tetrofosmin SPECT: comparison with [18F]FDG-PET. J Comput Assist Tomogr 2000; 24:574-580
70. Changlai SP, Tsai SC, Chou MC, et al. Whole body 18F-2-deoxyglucose positron emission tomography to restage non-small cell lung cancer. Oncol Rep 2001; 8:337-339
71. Vesselle H, Pugsley JM, Vallieres E, et al. The impact of fluorodeoxyglucose F 18 positron-emission tomography on the surgical staging of non-small cell lung cancer. J Thorac Cardiovasc Surg 2002; 124:511-519
72. Kernstine KH, Mclaughlin KA, Menda Y, et al. Can FDG-PET reduce the need for mediastinoscopy in potentially resectable nonsmall cell lung cancer? Ann Thorac Surg 2002; 73:394-401
73. Zimny M, Hochstenbag M, Lamers R, et al. Mediastinal staging of lung cancer with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography and a dual-head coincidence gamma camera. Eur Radiol 2003; 13:740-747
74. Konishi J, Yamazaki K, Tsukamoto E, et al. Mediastinal lymph node staging by FDG-PET in patients with non-small cell lung cancer: analysis of false-positive FDG-PET findings. Respiration 2003; 70:500-506
75. Gonzalez-Stawinski GV, Lemaire A, Merchant F, et al. A comparative analysis of positron emission tomography and mediastinoscopy in staging non-small cell lung cancer. J Thor Cardiovasc Surg 2003; 126:1900-1905
76. Fritscher-Ravens A, Bohuslavizki KH, Brandt L, et al. Mediastinal lymph node involvement in potentially resectable lung cancer: comparison of CT, positron emission tomography, and endoscopic ultrasonography with and without fine-needle aspiration. Chest 2003; 123:442-451
77. Demura Y, Tsuchida T, Ishizald T, et al. 18F-FDG accumulation with PET for differentiation between benign and malignant lesions in the thorax. J Nucl Med 2003; 44:540-548
78. Halpern BS, Schiepers C, Weber WA, et al. Presurgical staging of non-small cell lung cancer: positron emission tomography, integrated positron emission tomography/CT, and software image fusion. Chest 2005; 128:2289-2297
79. MacManus MP, Hicks RJ, Matthews JP, et al. High rate of unsuspected distant metastases by PET in apparent stage III non-small-cell lung cancer: implications for radical radiation therapy. Int J Radiat Oncol Biol Phys 2001; 50:287-293
80. van Tinteren H, Hoekstra O, Smit E, et al. Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small cell lung cancer: the PLUS Multicentre Randomised Trial. Lancet 2002; 359:1388-1393
81. Dietlein M, Weber K, Gandjour A, et al. Cost-effectiveness of FDG-PET for the. management of potentially operable non-small cell lung cancer: priority for a PET-based strategy after nodal-negative CT results. Eur J Nucl Med 2000; 27:1598-1609
82. Spiro SG, Porter JC. Lung cancer: where are we today? Current advances in staging and nonsurgical treatment. Am J Respir Crit Care Med 2002; 166:1166-1196
83. Scott W, Shepherd J, Gambhir S. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis. Ann Thorac Surg 1998; 66:1876-1883
84. Antoch G, Stattaus J, Nemat AT, et al. Non-small cell lung cancer: dual modality PET/CT in preoperative staging. Radiology 2003; 229:526-533
85. Roman MR, Rossleigh MA, Angelides S, et al. Staging and managing lung tumors using F-18 FDG coincidence detection. Clin Nucl Med 2001; 26:383-388
86. Crisci R, Di Cesare E, Lupattelli L, et al. MR study of N2 disease in lung cancer: contrast-enhanced method using gadolinium-DTPA. Eur J Cardiothorac Surg 1997; 11:214-217
87. Kernstine K, Stanford W, Mullen B, et al. PET, CT, and MR1 with Combidex for mediastinal staging in non-small cell lung carcinoma. Ann Thorac Surg 1999; 68:1022-1028
88. Padovani B, Mouroux J, Seksik L, et al. Chest wall invasion by bronchogenic carcinoma: evaluation with MR imaging. Radiology 1993; 187:33-38
89. Heelan R, Demas B, Caravelli J, et al. Superior sulcus tumors: CT and MR imaging. Radiology 1989; 170:637-641
90. Manfredi R, Pirronti T, Bonomo L, et al. Accuracy of computed tomography and magnetic resonance imaging in staging bronchogenic carcinoma. MAGMA 1996; 4:257-262
91. Shiotani S, Sugimura K, Sugihara M, et al. Diagnosis of chest wall invasion by lung cancer: useful criteria for exclusion of the possibility of chest wall invasion with MR imaging. Radiat Med 2000; 20:697-713
92. Silvestri G, Littenberg B, Colice G. The clinical evaluation for detecting metastatic lung cancer: a meta-analysis. Am J Respir Crit Care Med 1995; 152:225-230
93. Osaki T, Oyama T, Gu CD, et al. Prognostic impact of micrometastatic tumor cells in the lymph nodes and bone marrow of patients with completely resected stage 1 non-small-cell lung cancer. J Clin Oncol 2002; 20:2930-2936
94. Passlick B. Initial surgical staging of lung cancer. Lung Cancer 2003; 42(suppl):S21-S25
95. Cote RJ, Beattie EJ, Chaiwun B, et al. Detection of occult bone marrow micrometastases in patients with operable lung cancer. Ann Surg 1995; 222:415-423
96. Ohgami A, Mitsudomi T, Sugio K, et al. Micrometastatic tumor cells in the bone marrow of patients with non-small-cell lung cancer. Ann Thorac Surg 1997; 64:363-367
97. Pantel K, Izbicki J, Passlick B, et al. Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer. Lancet 1996; 347:649-653
98. Jiao X, Krasna MJ. Clinical significance of micrometastasis in lung and esophageal cancer: a new paradigm in thoracic oncology. Ann Thorac Surg 2002; 74:278-284
99. Arriagada R, Bergman B, Dunant A, et al. International Adjuvant Lung Cancer Trial Collaborative Group: cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-eell lung cancer. N Engl J Med 2004; 350:351-360
100. Hooper RG, Tenholder MF, Underwood, et al. Computed tomographic scanning in initial staging of bronchogenic carcinoma. Chest 1984; 85:774-777
101. Hooper RG, Beechler CR, Johnson MC. Radioisotope scanning in the initial staging of bronchogenic carcinoma. Am Rev Respir Dis 1978; 118:279-286
102. Turner P, Haggith JW. Preoperative radionuclide scanning in bronchogenic carcinoma. Chest 1981; 75:291-294
103. Ramsdell JW, Peters RM, Taylor AT, et al. Multiorgan scans for staging lung cancer: correlation with clinical evaluation. J Thorac Cardiovasc Surg 1977; 73:653-659
104. Tanaka K, Kubota K, Kodama T, et al. Extrathoracic staging is not necessary for non-small-cell lung cancer with clinical stage T1-2 N0. Ann Thorac Surg 1999; 68:1039-1042
105. Bilgin S, Yihnaz A, Ozdemir F, et al. Extrathoracic staging of non-small cell bronchogenic carcinoma: relationship of the clinical evaluation to organ scans. Respirology 2002; 7:57-61
106. Silvestri GA, Lenz JE, Harper SN, et al. The relationship of clinical findings to CT scan evidence of adrenal gland metastases in the staging of bronchogenic carcinoma. Chest 1992; 102:1748-1751
107. Grant D, Edwards D, Goldstraw P. Computed tomography of the brain, chest, and abdomen in the preoperative assessment of non-small cell lung cancer. Thorax 1988; 43:883-886
108. Tarver RD, Richmond BD, Klatte EC. Cerebral metastases from lung carcinoma: neurological and CT correlation work in progress. Radiology 1984; 153:689-692
109. Salvatierra A, Baamonde C, Llamas JM, et al. Extrathoracic staging of bronchogenic carcinoma. Chest 1990; 97:1052-1058
110. Hillers T, Sauve M, Guyatt G. Analysis of published studies on the detection of extrathoracic metastases in patients presumed to have operable non-small cell lung cancer. Thorax 1994; 49:14-19
111. Herder GJ, Verboom P, Smit EF, et al. Practice, efficacy and cost of staging suspected non-small-cell lung cancer: a retrospective study in two Dutch hospitals. Thorax 2002; 57:11-14
112. Pagani JJ. Non-small cell lung carcinoma adrenal metastases-computed tomography and percutaneous needle biopsy in their diagnosis. Cancer 1984; 53:1058-1060
113. Allard P, Yankaskas BC, Fletcher RH, et al. Sensitivity and specificity of computed tomography for the detection of adrenal metastatic lesions among 91 autopsied lung cancer patients. Cancer 1990; 66:457-462
114. Quinn DL, Ostrow LB, Porter DK, et al. Staging of non-small cell bronchogenic carcinoma - relationship of the clinical evaluation to organ scans. Chest 1986; 89:270-275
115. Guyatt GH, Cook DJ, Griffith LE, et al. Surgeons' assessment of symptoms suggesting extrathoracic metastases in patients with lung cancer. Ann Thorac Surg 1999; 68:309-315
116. Shahidi H, Kvale PA. Long-term survival following surgical treatment of solitary brain metastasis in non-small cell lung cancer. Chest 1996; 109:271-276
117. Urchel JD, Finley RK, Takita H. Long-term survival after bilateral adrenalectomy for metastatic lung cancer: a case report. Chest 1997; 112:848-850
118. Ichinose Y, Hara N, Ohta M, et al. Preoperative examination to detect distant metastases is not advocated for asymptomatic patients with stages I and II non-small cell lung cancer: preoperative examination for lung cancer. Chest 1989; 96:1104-1109
119. Hatter J, Hohman LJ, Mosca RS, et al. Preopertive evaluation of stage I and stage II non-small-cell lung cancer. Ann Thorac Surg 1994; 58:1738-1741
120. Canadian Lung Oncology Group. Investigating extrathoracic metastatic disease in patients with apparently operable lung cancer. Ann Thorac Surg 2001; 71:425-433
121. Graeber GM, Gupta NC, Murray GF. Positron emission tomographic imaging with fluorodeoxyglucose is efficacious in evaluating malignant pulmonary disease. J Thorac Cardiovasc Surg 1999; 117:719-727
122. Gupta N, Graeber G, Rogers J 2nd, et al. Comparative efficacy of positron emission tomography with FDG and computed tomographic scanning in preoperative staging of non-small cell lung cancer. Ann Surg 1999; 229:286-291
123. Verboom P, Herder GJ, Hoekstra OS, et al. Staging of non-small-cell lung cancer and applecation of FDG-PET: a cost modeling approach. Int J Technol Assess Health Care 2002; 18
124. Weder W, Schmid RA, Bruchhaus H, et al. Detection of extrathoracic metastases by positron emission tomography in lung cancer. Ann Thorac Surg 1998; 66:886-893
125. Erasmus J, Patz E Jr, McAdams H, et al. Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-fluorodeoxyglucose positron emission tomography. AJR Am J Roentgenol 1997; 168:1357-1360
126. Bury T, Barreto A, Daenen F, et al. Flourine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small-cell lung cancer. Eur J Nucl Med 1998; 25:1244-1247
127. Larcos G, Maisey MN. FDG-PET screening for cerebral metastases in patients with suspected malignancy. Nucl Med Commun 1996; 212:803-809
128. 18F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer. J Nucl Med 2001; 42:1596-1604
129. Valk PE, Pounds TR, Tesar RD, et al. Cost-effectiveness of PET imaging in clinical oncology. Nucl Med Biol 1996; 23:737-743
130. Verboom P, Van Tinteren H, Hoekstra OS, et al. Cost-effectiveness of FDG-PET in staging non-small-cell lung cancer: the PLUS study. Eur J Nucl Med Mol Imaging 2003; 30:1444-1449
131. Stroobants SG, D'Hoore I, Dooms C, et al. Additional value of whole-body fluorodeoxyglucose positron emission tomography in the detection of distant metastases of non-small-cell lung cancer. Clin Lung Cancer 2003; 4:242-247
132. Hany TF, Steinert HC, Goerres GW, et al. PET diagnostic accuracy: improvement with in-line PET-CT system; initial results. Radiology 2002; 225:575-581
133. Nielson ME, Heaston DK, Dunnick NR, et al. Preoperative CT evaluation of adrenal glands in non-small cell bronchogenic carcinoma. AJR Am J Roentgenol 1982; 139:317-320
134. Chapman GS, Kumar D, Redmond J, et al. Upper abdominal computerized tomography scanning in staging non-small cell lung carcinoma. Cancer 1984; 54:1541-1543
135. Pearlberg JL, Sandler MA, Beute GH, et al. T1N0M0 bronchogenic carcinoma: assessment by CT. Radiology 1985; 157:187-190
136. Heavey LR, Glazer GM, Gross BH, et al. The role of CT in staging radiographic T1N0M0 lung cancer. AJR Am J Roentgenol 1986; 146:285-290
137. Osada H, Nakajima Y, Taira Y, et al. The role of mediastinal and multi-organ CT scans in staging presumable surgical candidates with non-small-cell lung cancer. Jpn J Surg 1987; 17:362-368
138. Mirvis SE, Whitley NO, Aisner J, et al. Abdominal CT in the staging of small-cell carcinoma of the lung: incidence of metastases and effect on prognosis. AJR Am J Roentgenol 1987; 148:845-847
139. Whittlesey D. Prospective computed tomographic scanning in the staging of bronchogenic cancer. J Thorac Cardiovasc Surg 1988; 95:876-882
140. Ettinghausen SE, Burt ME. Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer. J Clin Oncol 1991; 9:1462-1466
141. Miralles TG, Gosabez F, de Lera J, et al. Percutaneous fine needle aspiration biopsy cytology of the liver for staging small cell lung carcinoma: comparison with other methods. Acta Cytol 1993; 37:499-502
142. Goerg C, Schwerk WB, Wolf M, et al. Adrenal masses in lung cancer: sonographic diagnosis and follow-up. Eur J Cancer 1992; 28A:1400-1403
143. Oliver T Jr, Bernardino M, Miller J, et al. Isolated adrenal masses in non-small cell bronchogenic carcinoma. Radiology 1984; 153:217-218
144. Burt M, Heelan R, Coit D, et al. Prospective evaluation of unilateral adrenal masses in patients with operable non-small cell lung cancer: impact of magnetic resonance imaging. J Thorac Cardiovasc Surg 1994; 107:584-588
145. Eggesbo HB, Hansen G. Clinical impact of adrenal expansive lesions in bronchial carcinoma. Acta Radiol 1996; 37:343-347
146. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-(F-18)-fluoro-2-deoxy-D-glueose. Radiology 1995; 194:131-134
147. Gillams A, Roberts CM, Shaw P, et al. The value of CT scanning and percutaneous fine needle aspiration of adrenal masses in biopsy-proven lung cancer. Clin Radiol 1992; 46:18-22
148. Macari M, Rofsky NM, Naidich DP, et al. Non-small cell lung carcinoma: usefulness of unenhanced helical CT of the adrenal glands in an unmonitored environment. Radiology 1998; 209:807-881
149. Porte HL, Ernst OJ, Delebecq T, et al. Is computed tomography guided biopsy still necessary for the diagnosis of adrenal masses in patients with resectable non-small cell lung cancer. Eur J Cardiothorac Surg 1999; 15:597-601
150. Heinz-Peer G, Honigschnabi S, Schneider B, et al. Characterization of adrenal masses using MR imaging with histopathologic correlation. AJR Am J Roentgenol 1999; 173:15-22
151. Gross MD, Shapiro B, Bouffard JA, et al. Distinguishing benign from malignant euadrenal masses. Ann Intern Med 1988; 109:613-618
152. Butler AR, Leo JS, Lin JP, et al. The value of routine cranial computed tomography in neurologically intact patients with primary carcinoma of the lung. Radiology 1979; 131:339-401
153. Cole JFH, Thomas JE, Wilcox AB, et al. Cerebral imaging in the asymptomatic preoperative bronchogenic carcinoma patient: is it worthwhile? Ann Thorac Surg 1994; 57:838-840
154. Colice GL, Birkmeyer JD, Black WC, et al. Cost-effectiveness of head CT in patients with lung cancer without clinical evidence of metastases. Chest 1995; 108:1264-1271
155. Jacobs L, Kinkel WR, Vincent RG. 'Silent' brain metastasis from lung carcinoma determined by computerized tomography. Arch Neurol 1977; 77:690-693
156. Mintz BJ, Turhim S, Alexander S, et al. Intracranial metastases in the initial staging of bronchogenic carcinoma. Chest 1984; 86:850-853
157. Ferrigno D, Buccheri G. Cranial computed tomography as a part of the initial staging procedures for patients with non-small cell lung cancer. Chest 1994; 106:1025-1029
158. Kormas P, Bradshaw J, Jeyasingham K. Preoperative computed tomography of the brain in non-small cell bronchogenic carcinoma. Thorax 1992; 47:106-108
159. Jennings EC, Aungst CW, Yatco R. Asymptomatic patients with primary carcinoma; computerized axial tomography study. N Y State J Med 1980; 80:1096-1098
160. Johnson DH, Windham WW, Allen JH, et al. Limited value of CT brain scans in the staging of small cell lung cancer. AJR Am J Roentgenol 1983; 140:37-40
161. Levitan N, Hong WK, Byrne RE, et al. Role of computerized cranial tomography in the staging of small cell carcinoma of the lung. Cancer Treat Rep 1984; 68:1375-1377
162. Crane JM, Nelson MJ, Ihde DC, et al. A comparison of computed tomography and radionuclide scanning for detection of brain metastases in small cell lung cancer. J Clin Oncol 1984; 2:1017-1024
163. Habets JM, van Oosterhout AG, ten Velde GP, et al. Diagnostic value of CT in the detection of brain metastasis in small cell lung cancer patients. J Belge Radiol 1992; 75:179-181
164. Yokio K, Kamiya N, Matsuguma H, et al. Detection of brain 'metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest 1999; 115:714-719
165. Patchell R, Tibbs P, Walsh J, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500
166. Davis PC, Hudgins PA, Peterman SB, et al. Diagnosis of cerebral metastases: double-dose delayed CT vs contrast-enhanced MR imaging. AJR Am J Roentgenol 1991; 156:1039-1046
167. Earnest F, Ryu J, Miller G, et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for detection: pilot study. Radiology 1999; 211:137-145
168. Hochstenbag MM, Twijnstra A, Hofman P, et al. MR-imaging of the brain of neurologic asymptomatic patients with large cell or adenocarcinoma of the lung: does it influence prognosis and treatment? Lung Cancer 2003; 42:189-193
169. Griffeth LK, Rich KM, Dehdashti F, et al. Brain metastases from non-central nervous system tumors: evaluation with PET. Radiology 1993; 186:37-44
170. Tornyos K, Garcia O, Karr B, et al. A correlation study of bone scanning with clinical and laboratory findings in the staging of non-small cell lung cancer. Clin Nucl Med 1991; 16:107-109
171. Michel F, Soler M, Imhof E, et al. Initial staging of non-small cell lung cancer; value of routine radioisotope bone scanning. Thorax 1991; 46:469-473
172. Schirrmeister H, Arslandemir C, Glatting G, et al. Omission of bone scanning according to staging guidelines leads to futile therapy in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2004; 31:964-968
173. Hsia TC, Shen YY, Yen RF, et al. Comparing whole body 18F-2-deoxyglucose positron emission tomography and technetium-99m methylene diophosphate bone scan to detect bone metastases in patients with non-small cell lung cancer. Neoplasma 2002; 49:267-271
174. Carretta A, Ciriaco P, Canneto B, et al. Therapeutic strategy in patients with non-small cell lung cancer associated to satellite pulmonary nodules. Eur J Cardiothorac Surg 2002; 21:1100-1104
175. Erasmus JJ, McAdams HP, Rossi SE, et al. FDG PET of pleural effusions in
176. Gupta NC, Rogers JS, Graeber GM, et al. Clinical role of F-18 fluorodeoxyglucose positron emission tomography imaging in patients with lung cancer and suspected malignant pleural effusion. Chest 2002; 122:1918-1924
177. Duysinx B, Nguyen D, Louis R, et al. Evaluation of pleural disease with 18-fluorodeoxyglucose positron emission tomography imaging. Chest 2004; 125:489-493
178. Berlangieri SU, Scott AM, Knight SR, et al. F-18 fluorodeoxyglucose position emission tomography in the non-invasive staging of non-small cell lung cancer. Eur J Cardiothorac Surg 1999; 16(suppl):S25-S30
179. Kobayashi J, Kitamura S. Evaluation of lymph nodes on computed tomography images in epidermoid lung cancer. Intern Med 1995; 34:507-513
180. Seely JM, Mayo JR, Miller RR, et al. T1 lung cancer: prevalence of mediastinal modal metastases and diagnostic accuracy of CT. Radiology 1993; 186:129-132
181. Izbicki JR, Thetter O, Karg O, et al. Accuracy of computed tomographic scan and surgical assessment for staging of bronchial carcinoma: a prospective study. J Thorac Cardiovasc Surg 1992; 104:413-420
182. 11C-methionine for the detection of hilar and mediastinal lymph node metastasis in lung cancer. J Nucl Med 2000; 41:283-290
183. Sasaki M, Ichiya Y, Kuwabara Y, et al. The usefulness of FDG positron emission tomography for the detection of mediastinal lymph node metastases in patients with non-small cell lung cancer: a comparative study with x-ray computed tomography. Eur J Nucl Med 1996; 23:741-747